WO2010054379A3 - Gene signature for predicting prognosis of patients with solid tumors - Google Patents

Gene signature for predicting prognosis of patients with solid tumors Download PDF

Info

Publication number
WO2010054379A3
WO2010054379A3 PCT/US2009/063883 US2009063883W WO2010054379A3 WO 2010054379 A3 WO2010054379 A3 WO 2010054379A3 US 2009063883 W US2009063883 W US 2009063883W WO 2010054379 A3 WO2010054379 A3 WO 2010054379A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
solid tumors
associated genes
gene signature
expression
Prior art date
Application number
PCT/US2009/063883
Other languages
French (fr)
Other versions
WO2010054379A2 (en
Inventor
Xin Wei Wang
Stephanie K. Roessler
Original Assignee
The United States Of America, As Represensted By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represensted By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represensted By The Secretary, Department Of Health And Human Services
Priority to US13/127,701 priority Critical patent/US8735082B2/en
Priority to EP09752261.9A priority patent/EP2352847B1/en
Publication of WO2010054379A2 publication Critical patent/WO2010054379A2/en
Publication of WO2010054379A3 publication Critical patent/WO2010054379A3/en
Priority to US14/252,005 priority patent/US9394358B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Abstract

Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLCl, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression of SH2D4A, CCDC25, ELP3, DLCl, PROSC and S0RBS3 in solid tumors is associated with a poor prognosis, while a decrease in DNA copy number or mRNA expression of HNRPD, PAQR3, PHF17 and DCK in solid tumors is associated with a good prognosis. Thus, provided herein is a method of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one of more tumor-associated genes in a tumor sample and comparing expression of the one or more tumor-associated genes in the tumor sample to a control. Also provided is a method of treating a patient diagnosed with HCC or breast cancer by administering a therapeutically effective amount of an agent that alters expression or activity of one or more of the disclosed tumor- associated genes. Further provided are arrays comprising probes or antibodies specific for a plurality of tumor-associated genes or proteins.
PCT/US2009/063883 2008-11-10 2009-11-10 Gene signature for predicting prognosis of patients with solid tumors WO2010054379A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/127,701 US8735082B2 (en) 2008-11-10 2009-11-10 Gene signature for predicting prognosis of patients with solid tumors
EP09752261.9A EP2352847B1 (en) 2008-11-10 2009-11-10 Gene signature for predicting prognosis of patients with solid tumors
US14/252,005 US9394358B2 (en) 2008-11-10 2014-04-14 Gene signature for predicting prognosis of patients with solid tumors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19881308P 2008-11-10 2008-11-10
US61/198,813 2008-11-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/127,701 A-371-Of-International US8735082B2 (en) 2008-11-10 2009-11-10 Gene signature for predicting prognosis of patients with solid tumors
US14/252,005 Division US9394358B2 (en) 2008-11-10 2014-04-14 Gene signature for predicting prognosis of patients with solid tumors

Publications (2)

Publication Number Publication Date
WO2010054379A2 WO2010054379A2 (en) 2010-05-14
WO2010054379A3 true WO2010054379A3 (en) 2010-09-30

Family

ID=41615832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/063883 WO2010054379A2 (en) 2008-11-10 2009-11-10 Gene signature for predicting prognosis of patients with solid tumors

Country Status (3)

Country Link
US (2) US8735082B2 (en)
EP (2) EP2687609B1 (en)
WO (1) WO2010054379A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011047269A2 (en) * 2009-10-15 2011-04-21 The University Of North Carolina At Chapel Hill Elongator proteins and use thereof as dna demethylases
US20160122825A1 (en) * 2012-06-26 2016-05-05 Board Of Regents, The University Of Texas System Efficient functional genomics platform
WO2014020444A2 (en) * 2012-08-01 2014-02-06 Pacylex Pharmaceuticals Inc. Methods and compositions for diagnosis and prognosis in breast cancer
KR20150058465A (en) * 2012-09-21 2015-05-28 싱가포르 헬스 서비시즈 피티이. 엘티디. Methods of diagnosing liver cancer in a subject and a kit for diagnosing liver cancer
CN110172515A (en) * 2019-06-04 2019-08-27 朱义芳 Application of the CNTN3 albumen in glioma Index for diagnosis
CN111190007B (en) * 2020-01-07 2022-02-25 中山大学孙逸仙纪念医院 Application of CCDC25 in predicting breast cancer prognosis and inhibiting breast cancer distant organ metastasis
CN112877440B (en) * 2021-04-20 2023-04-14 桂林医学院附属医院 Application of biomarker in prediction of liver cancer recurrence

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050227255A9 (en) * 1998-02-25 2005-10-13 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services DLC-1 gene deleted in cancers
WO2005108615A2 (en) * 2004-04-14 2005-11-17 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
WO2006016110A1 (en) * 2004-08-10 2006-02-16 University College Cardiff Consultants Limited Methods and kit for the prognosis of breast cancer
WO2007063118A1 (en) * 2005-11-30 2007-06-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for hepatocellular carcinoma classificastion and prognosis
US20080206769A1 (en) * 2007-01-31 2008-08-28 Applera Corporation Molecular prognostic signature for predicting breast cancer distant metastasis, and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2548112B2 (en) 1983-09-02 1996-10-30 シンジェン，インコーポレイテッド Carrier and oligonucleotide synthesis
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5219727A (en) 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
DE69432791T2 (en) 1993-05-28 2004-06-03 Baylor College Of Medicine, Houston METHOD AND MASS SPECTROMETER FOR DESORPTION AND IONIZATION OF ANALYZES
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
EP0758403B1 (en) 1994-05-05 1998-06-24 Beckman Instruments, Inc. Oligonucleotide repeat arrays
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
IL122349A0 (en) 1995-06-07 1998-04-05 Univ Yale Adeno-associated viral vectors
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6344445B1 (en) 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
US20030083289A1 (en) 1995-10-19 2003-05-01 Boursnell Michael Edward Griffith Herpesvirus vectors and their uses
US5716784A (en) 1996-02-05 1998-02-10 The Perkin-Elmer Corporation Fluorescence detection assay for homogeneous PCR hybridization systems
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
US6423692B2 (en) * 1997-04-24 2002-07-23 Dana-Farber Cancer Institute, Inc. Method of enhancing the effectiveness of DCK phosphorylated molecules
FR2762615B1 (en) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med NEW INTERNAL RIBOSOME ENTRY SITE AND VECTOR CONTAINING THE SAME
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US5985567A (en) 1997-08-15 1999-11-16 Beckman Coulter, Inc. Hybridization detection by pretreating bound single-stranded probes
US6642051B1 (en) 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6013789A (en) 1998-02-20 2000-01-11 Beckman Coulter, Inc. Covalent attachment of biomolecules to derivatized polypropylene supports
WO1999043812A2 (en) 1998-02-25 1999-09-02 The United States Of America, Represented By The Secretary, Department Of Health & Human Services, National Institutes Of Health Dlc-1 gene, a putative tumors suppressor gene
DE19813835A1 (en) * 1998-03-20 1999-09-23 Metagen Gesellschaft Fuer Genomforschung Mbh Human nucleic acid sequences and protein products from normal breast tissue, useful for breast cancer therapy
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
GB9826069D0 (en) 1998-11-28 1999-01-20 Univ Leeds HIV vaccine
EP2314700A1 (en) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
DE19905501B4 (en) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie A method of producing a recombinant adeno-associated virus, suitable compositions therefor, and use for the manufacture of a medicament
CA2368247A1 (en) 1999-04-27 2000-11-09 Ciphergen Biosystems, Inc. Probes for a gas phase ion spectrometer
CA2375880A1 (en) 1999-06-22 2000-12-28 Dnavec Research Inc. A vector for the expression of two foreign genes
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US20040029114A1 (en) * 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US7211247B2 (en) 2001-04-09 2007-05-01 University Of Southern California Lentivirus vectors for gene transfer to alveolar epithelial cells
US20040005644A1 (en) * 2002-02-28 2004-01-08 Su Yan A. Method and composition for detection and treatment of breast cancer
US20030228689A1 (en) 2002-05-31 2003-12-11 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor kinase 6 expression
GB0222276D0 (en) * 2002-09-25 2002-10-30 Inst Of Molecul & Cell Biology Methods
WO2004081029A2 (en) 2003-03-13 2004-09-23 Ramot At Tel Aviv University Ltd. Novel non-invasive marker for liver disease
CA2523798A1 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
JP2007516693A (en) * 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Compositions and methods for the treatment and diagnosis of cancer
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
WO2005116224A2 (en) 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
US7943306B2 (en) * 2005-01-12 2011-05-17 The Board Of Trustees Of The Leland Stanford Junior University Gene expression signature for prediction of human cancer progression
ATE525092T1 (en) 2005-05-02 2011-10-15 Genzyme Corp GENE THERAPY FOR NEUROMETABOLIC DISEASES
JP2008546387A (en) * 2005-06-13 2008-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Compositions and methods for treating and diagnosing cancer
WO2007030531A2 (en) 2005-09-06 2007-03-15 Molecular Image Inc. Reagents for testing and molecular imaging of liver cancer
US20070218512A1 (en) * 2006-02-28 2007-09-20 Alex Strongin Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
WO2007143752A2 (en) * 2006-06-09 2007-12-13 The Regents Of The University Of California Targets in breast cancer for prognosis or therapy
US8202968B2 (en) 2006-10-20 2012-06-19 Washington University Predicting lung cancer survival using gene expression
RU2473555C2 (en) * 2006-12-19 2013-01-27 ДжинГоу, Инк. New method for functional analysis of body of experimental data and gene groups identified from said data
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
US20080254456A1 (en) * 2007-04-16 2008-10-16 Jung-Yaw Lin Gene marker for human hepatocellular carcinoma diagnosis
TWI552751B (en) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050227255A9 (en) * 1998-02-25 2005-10-13 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services DLC-1 gene deleted in cancers
WO2005108615A2 (en) * 2004-04-14 2005-11-17 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
WO2006016110A1 (en) * 2004-08-10 2006-02-16 University College Cardiff Consultants Limited Methods and kit for the prognosis of breast cancer
WO2007063118A1 (en) * 2005-11-30 2007-06-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for hepatocellular carcinoma classificastion and prognosis
US20080206769A1 (en) * 2007-01-31 2008-08-28 Applera Corporation Molecular prognostic signature for predicting breast cancer distant metastasis, and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"AFFYMETRIX CATALOG; PRODUKT: HUMAN GENOME U133A ARRAY; ARRAY FINDER", AFFYMETRIX PRODUCT CATALOG, XX, XX, 1 July 2002 (2002-07-01), pages 1, XP002267612 *
LEE JU-SEOG ET AL: "Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 40, no. 3, 1 September 2004 (2004-09-01), pages 667 - 676, XP002535848, ISSN: 0270-9139 *
PATIL MOHINI A ET AL: "Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma", CARCINOGENESIS, OXFORD UNIVERSITY PRESS, GB, vol. 26, no. 12, 1 December 2005 (2005-12-01), pages 2050 - 2057, XP002545494, ISSN: 0143-3334, [retrieved on 20050706] *
ROESSLER STEPHANIE ET AL: "Future of molecular profiling of human hepatocellular carcinoma", FUTURE ONCOLOGY, FUTURE MEDICINE LTD., LONDON, GB, vol. 3, no. 4, 1 August 2007 (2007-08-01), pages 429 - 439, XP009129413, ISSN: 1479-6694 *
XUE WEN ET AL: "DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma", GENES & DEVELOPMENT, vol. 22, no. 11, June 2008 (2008-06-01), pages 1439 - 1444, XP002568895, ISSN: 0890-9369 *

Also Published As

Publication number Publication date
EP2687609A3 (en) 2014-04-23
EP2687609A2 (en) 2014-01-22
US9394358B2 (en) 2016-07-19
EP2687609B1 (en) 2017-01-04
EP2352847A2 (en) 2011-08-10
WO2010054379A2 (en) 2010-05-14
US20140220043A1 (en) 2014-08-07
EP2352847B1 (en) 2014-01-08
US20110206703A1 (en) 2011-08-25
US8735082B2 (en) 2014-05-27

Similar Documents

Publication Publication Date Title
Pei et al. TOP2A induces malignant character of pancreatic cancer through activating β-catenin signaling pathway
Hasan et al. Advances in pancreatic cancer biomarkers
Zhang et al. A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy
Zhang et al. P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression
Wang et al. miR-133a represses tumour growth and metastasis in colorectal cancer by targeting LIM and SH3 protein 1 and inhibiting the MAPK pathway
WO2010054379A3 (en) Gene signature for predicting prognosis of patients with solid tumors
Chen et al. MiR-410 regulates MET to influence the proliferation and invasion of glioma
Bewick et al. Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer
Khella et al. Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses
Huo et al. miR‑128‑3p inhibits glioma cell proliferation and differentiation by targeting NPTX1 through IRS‑1/PI3K/AKT signaling pathway
Zhen et al. Knockdown of SNHG8 repressed the growth, migration, and invasion of colorectal cancer cells by directly sponging with miR-663
JP2007507222A5 (en)
WO2013098797A3 (en) Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
WO2006121991A3 (en) Compositions and methods for detection, prognosis and treatment of breast cancer
Wang et al. MicroRNA-195 inhibits human gastric cancer by directly targeting basic fibroblast growth factor
Jiang et al. Long noncoding RNA LINC00961 inhibits cell invasion and metastasis in human non-small cell lung cancer
Moschovis et al. Long non-coding RNA in pancreatic adenocarcinoma and pancreatic neuroendocrine tumors
Lacerda-Abreu et al. Inorganic phosphate transporters in cancer: Functions, molecular mechanisms and possible clinical applications
Kwon Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer
Aprile et al. Emerging role of oncogenic long noncoding RNA as cancer biomarkers
Lin et al. SRPX2, an independent prognostic marker, promotes cell migration and invasion in hepatocellular carcinoma
Dong et al. Diagnostic and predictive significance of serum microRNA-7 in esophageal squamous cell carcinoma
Villegas et al. Identification of novel non-coding RNA-based negative feedback regulating the expression of the oncogenic transcription factor GLI1
WO2010093872A3 (en) Molecular-based method of cancer diagnosis and prognosis
Bagley et al. Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09752261

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13127701

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009752261

Country of ref document: EP